1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials

BACKGROUND: GEMINI 1 & 2 are global double-blind, multi-center phase III non-inferiority studies evaluating efficacy and safety of dolutegravir (DTG) + lamivudine (3TC) once daily in treatment-naive HIV-1-infected adults with Screening HIV-1 RNA ≤ 500,000 c/mL (ClinicalTrials.gov: NCT02831673/NC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ait-Khaled, Mounir, Man, Choy, Sievers, Jorg, Grove, Richard, Wynne, Brian, Urbaityte, Rimgaile, van Wyk, Jean A, Madero, Juan G Sierra, Gulminetti, Roberto, Estrada, Vicente, Hagins, Debbie, Zolopa, Andrew, Tsai, Hung-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776490/
http://dx.doi.org/10.1093/ofid/ofaa439.1210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776490/
http://dx.doi.org/10.1093/ofid/ofaa439.1210

Ejemplares similares